Meanwhile a new variant JN.1 is gaining traction in New Zealand, and stocks of the Paxlovid antiviral are running low.
This is a companion discussion topic for the original entry at https://www.sciencemediacentre.co.nz/2023/12/18/covid-19-over-the-holidays-expert-reaction/